carmustine

also known as BCNU · Gliadel · DTI-015 · Gliadel wafers · NSC-409962 · 1,3-bis(2-chloroethyl)-1-nitrosourea · Becenun · BiCNU · +13 more

Small molecule targets GSR via inhibition

Developed for: lymphoma · central nervous system neoplasm · plasma cell myeloma · glioblastoma · non-Hodgkin lymphoma · Hodgkins lymphoma · mantle cell lymphoma · leukemia
+68 more
· peripheral T-cell lymphoma, not otherwise specified · cancer of unknown primary site · chronic lymphocytic leukemia/small lymphocytic lymphoma · diffuse large B-cell lymphoma · gliosarcoma · anaplastic astrocytoma · anaplastic oligodendroglioma · brain cancer · brain neoplasm · Burkitt lymphoma · follicular lymphoma · metastatic malignant neoplasm · primary central nervous system lymphoma · primary cutaneous T-cell non-Hodgkin lymphoma · Waldenstrom macroglobulinemia · anaplastic large cell lymphoma · anaplastic oligoastrocytoma · breast cancer · cutaneous melanoma · extranodal nasal NK/T cell lymphoma · hepatosplenic T-cell lymphoma · HIV infectious disease · intraocular lymphoma · large-cell immunoblastic lymphoma · malignant glioma · MALT lymphoma · metastatic malignant neoplasm in the brain · mycosis fungoides and variants · nodal marginal zone B-cell lymphoma · plasma cell neoplasm · splenic marginal zone lymphoma · testicular lymphoma · astrocytoma (excluding glioblastoma) · B-cell non-Hodgkin lymphoma · central nervous system cancer · central nervous system vasculitis · cerebellar degeneration · childhood malignant neoplasm · chronic inflammatory demyelinating polyradiculoneuropathy · colorectal cancer · glioma · head and neck cancer · high-grade B-cell lymphoma double-hit/triple-hit · Lambert-Eaton myasthenic syndrome · metastatic melanoma · mixed glioma · myasthenia gravis · myelodysplastic syndrome · neuromyelitis optica · oligodendroglial tumor · opsoclonus-myoclonus syndrome · ovarian cancer · plasma cell leukemia · primary brain neoplasm · prostate cancer · Rasmussen subacute encephalitis · relapsing-remitting multiple sclerosis · sarcoma · small intestine cancer · stiff-person syndrome · triple-negative breast carcinoma · urinary bladder cancer · urothelial carcinoma · uveal melanoma · breast carcinoma · malignant pancreatic neoplasm · myelodysplastic/myeloproliferative neoplasm · T-cell non-Hodgkin lymphoma
Investigated by: National Cancer Institute (NCI) · Duke University · Alliance for Clinical Trials in Oncology · Memorial Sloan Kettering Cancer Center · SWOG Cancer Research Network · University of Maryland, Baltimore
+88 more
· European Organisation for Research and Treatment of Cancer - EORTC · Fred Hutchinson Cancer Center · Genentech, Inc. · University of Nebraska · Cancer and Leukemia Group B · Case Comprehensive Cancer Center · Eastern Cooperative Oncology Group · Eisai Inc. · M.D. Anderson Cancer Center · Radiation Therapy Oncology Group · University of Maryland Greenebaum Cancer Center · City of Hope Medical Center · Direct Therapeutics · Masonic Cancer Center, University of Minnesota · Washington University School of Medicine · Barbara Ann Karmanos Cancer Institute · Cancer Research UK · Fondazione Italiana Linfomi - ETS · Medical Research Council · National Heart, Lung, and Blood Institute (NHLBI) · Roswell Park Cancer Institute · Shandong Lanjin Pharmaceuticals Co.,Ltd · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Stanford University · University of California, Davis · Andres J. M. Ferreri · Andrés José Maria Ferreri · Arbor Pharmaceuticals, Inc. · Assistance Publique Hopitaux De Marseille · Barrett Cancer Center · Blood and Marrow Transplant Clinical Trials Network · Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte · Charite University, Berlin, Germany · Children's Oncology Group · Columbia University · Cordgenics, LLC · EBMT Solid Tumors Working Party · Emory University · European Inter-group Cooperation on Childhood and Adolescent Non Hodgkin Lymphoma · French Innovative Leukemia Organisation · GIMEMA Foundation · General Oncology, Inc. · Georg Hess, MD · German CLL Study Group · German Hodgkin's Lymphoma Study Group · German Low Grade Lymphoma Study Group · Gruppo Italiano Studio Linfomi · Heidelberg University · Herbert Irving Comprehensive Cancer Center · INSYS Therapeutics Inc · Immune Tolerance Network (ITN) · International Extranodal Lymphoma Study Group (IELSG) · Jun Zhu · Karyopharm Therapeutics Inc · Klinikum Frankfurt Höchst · LMU Klinikum · Leland Metheny · Lisata Therapeutics, Inc. · Lymphoma Study Association · Lymphoma Trials Office · Medical College of Wisconsin · Montefiore Medical Center · Mundipharma Pte Ltd. · Myriad Genetics, Inc. · NCIC Clinical Trials Group · National Institute of Allergy and Infectious Diseases (NIAID) · National Institute of Medical Sciences and Nutrition Salvador Zubiran · National Marrow Donor Program · National Research Center for Hematology, Russia · New Approaches to Brain Tumor Therapy Consortium · Nobelpharma · Nordic Lymphoma Group · NovoCure Ltd. · PETHEMA Foundation · all 94 on the full record

Regulatory milestones approvals, filings & regulatory actions · 3 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Approved	EU (EMA)	Carmustine medac (previously Carmustine Obvius)	—	2018-07-18	europa.eu ↗
Label expansion	US (FDA)	GLIADEL	—	2003-02-25	fda.gov ↗
Approved	US (FDA)	BICNU	—	1977-03-07	fda.gov ↗

Trials 142 · started per year

today

US approved 1977

EU approved 2018

19761977197819791980198119821983198419851986198719881989199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 112 trials
Phase 1	NCT04150042	Jan 2021 → Dec 2028 expected	BRCA1-related cancer predisposition, BRCA2-related cancer predisposition, Her2-receptor negative breast cancer, PALB2-related cancer predisposition +3	General Oncology, Inc.	Recruiting	No outcome recorded
Phase 1	NCT02343666	Aug 2016 → Aug 2020	HIV infectious disease, Hodgkins lymphoma, non-Hodgkin lymphoma	Fred Hutchinson Cancer Center	Withdrawn	No outcome recorded Stop: Enrollment
Phase 1	NCT00641381	May 2000 → Feb 2026	lymphoma	City of Hope Medical Center	Completed	No outcome recorded
Phase 1	NCT00003765	May 1999 → Mar 2006	central nervous system neoplasm	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 1	NCT00003567	May 1999 → Jan 2007	cancer of unknown primary site, central nervous system neoplasm, lymphoma	Case Comprehensive Cancer Center	Terminated	No outcome recorded Stop: Enrollment
Phase 1	NCT00003613	Apr 1999 → May 2006	primary cutaneous T-cell non-Hodgkin lymphoma	National Cancer Institute (NCI)	Terminated	No outcome recorded
Phase 1	NCT00003876	Apr 1999 → May 2004	central nervous system cancer	Barrett Cancer Center	Completed	No outcome recorded
Phase 1	NCT00003348	May 1998 → Aug 2000	central nervous system neoplasm	Duke University	Completed	No outcome recorded
Phase 1	NCT00002988	Apr 1997 → Nov 2000	central nervous system neoplasm	Duke University	Completed	No outcome recorded
Phase 1	NCT00002986	Feb 1997 → May 2004	central nervous system neoplasm	Duke University	Completed	No outcome recorded
Phase 1	NCT00004028	Sep 1996 → ?	central nervous system neoplasm	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 1	NCT00002604	Jan 1996 → Jul 2000	cancer of unknown primary site	Case Comprehensive Cancer Center	Completed	No outcome recorded

Phase 1/29 trials
Phase 1/2	NCT04421378	Jun 2020 → Jul 2023	glioblastoma	Karyopharm Therapeutics Inc	Terminated	No outcome recorded
Phase 1/2	NCT00961220	Feb 2010 → Apr 2012	mycosis fungoides and variants, primary cutaneous T-cell non-Hodgkin lymphoma	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 1/2	NCT00919737	Jun 2009 → Apr 2011	malignant glioma	Nobelpharma	Completed	No outcome recorded
Phase 1/2	NCT00669669	Feb 2009 → Jul 2018	gliosarcoma	Fred Hutchinson Cancer Center	Terminated	No outcome recorded Stop: Business
Phase 1/2	NCT00027612	Jul 2002 → Oct 2006	central nervous system neoplasm	Alliance for Clinical Trials in Oncology	Completed	No outcome recorded
Phase 1/2	NCT00046852	Dec 2001 → Nov 2004	infectious disease, plasma cell myeloma	University of Maryland, Baltimore	Completed	No outcome recorded
Phase 1/2	NCT00009854	Jun 2000 → ?	central nervous system neoplasm, metastatic malignant neoplasm	Direct Therapeutics	Unknown	No outcome recorded
Phase 1/2	NCT00003417	Sep 1998 → May 2004	central nervous system neoplasm	Radiation Therapy Oncology Group	Completed	No outcome recorded
Phase 1/2	NCT00038441	Sep 1995 → Feb 2003	brain neoplasm, malignant glioma	M.D. Anderson Cancer Center	Completed	No outcome recorded
Phase 289 trials · 3 met primary · 3 missed
Phase 2	NCT06915246	Mar 2025 → Mar 2027 expected	Hodgkins lymphoma, non-Hodgkin lymphoma	VIVUS LLC	Recruiting	No outcome recorded
Phase 2	NCT06687772	Jan 2025 → Jul 2027 expected	diffuse large B-cell lymphoma	Washington University School of Medicine	Recruiting	No outcome recorded
Phase 2	NCT05052957	Jan 2023 → Nov 2026 expected	adult glioblastoma, gliosarcoma	Leland Metheny	Recruiting	No outcome recorded
Phase 2	NCT04728633	Sep 2021 → Jan 2027 expected	metastatic malignant neoplasm, uveal melanoma	Thomas Jefferson University	Active not recruiting	No outcome recorded
Phase 2	NCT05425654	May 2021 → May 2023	primary central nervous system lymphoma	National Research Center for Hematology, Russia	Unknown	No outcome recorded
Phase 2	NCT04222062	Nov 2020 → Dec 2028 expected	metastatic malignant neoplasm in the brain	University of Nebraska	Recruiting	No outcome recorded
Phase 2	NCT03570983	Sep 2018 → Jun 2024	plasma cell myeloma	Swedish Medical Center	Unknown	No outcome recorded
Phase 2	NCT02670109	Feb 2018 → Nov 2020	triple-negative breast carcinoma	National Institute of Medical Sciences and Nutrition Salvador Zubiran	Unknown	No outcome recorded
Phase 2	NCT03629873	Feb 2018 → Dec 2021	diffuse large B-cell lymphoma, high-grade B-cell lymphoma double-hit/triple-hit, mantle cell lymphoma, peripheral T-cell lymphoma, not otherwise specified	The First Affiliated Hospital with Nanjing Medical University	Unknown	No outcome recorded
Phase 2	NCT03019640	Oct 2017 → Aug 2021	diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma	M.D. Anderson Cancer Center	Completed	No outcome recorded
Phase 2	NCT03125642	Apr 2017 → Sep 2026 overdue	Hodgkins lymphoma, non-Hodgkin lymphoma	Masonic Cancer Center, University of Minnesota	Recruiting	No outcome recorded
Phase 2	NCT02788201	Mar 2017 → Oct 2019	urinary bladder cancer, urothelial carcinoma	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 2	NCT02348255	Jan 2016 → Jan 2017	brain neoplasm, glioblastoma	University of California, Davis	Withdrawn	No outcome recorded Stop: Enrollment
Phase 2	NCT02399189	May 2014 → Apr 2017	primary central nervous system lymphoma	Jun Zhu	Unknown	No outcome recorded
Phase 2	NCT01511562	Sep 2012 → Jan 2021	lymphoma	Alliance for Clinical Trials in Oncology	Completed	Met primary
Phase 2	NCT01653418	Sep 2012 → Aug 2013	plasma cell myeloma	Washington University School of Medicine	Terminated	No outcome recorded
Phase 2	NCT01692691	Aug 2012 → Oct 2014	metastatic melanoma	Western Regional Medical Center	Terminated	No outcome recorded
Phase 2	NCT01500161	Nov 2011 → Nov 2013	B-cell chronic lymphocytic leukemia, Hodgkins lymphoma, acute myeloid leukemia, aplastic anemia +3	Texas Oncology Cancer Center	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT01516593	Nov 2011 → Apr 2013	Burkitt lymphoma, HIV infectious disease	Andres J. M. Ferreri	Completed	No outcome recorded
Phase 2	NCT01310868	May 2011 → Mar 2015	glioblastoma	University College, London	Completed	No outcome recorded
Phase 2	NCT01186406	Apr 2011 → Jun 2014	gliosarcoma	Duke University	Terminated	No outcome recorded
Phase 2	NCT01008462	Mar 2010 → Jun 2018	B-cell prolymphocytic leukemia, Hodgkins lymphoma, T-cell prolymphocytic leukemia, Waldenstrom macroglobulinemia +4	Fred Hutchinson Cancer Center	Completed	No outcome recorded
Phase 2	NCT01011920	Nov 2009 → Mar 2015	primary central nervous system lymphoma	International Extranodal Lymphoma Study Group (IELSG)	Completed	Met primary
Phase 2	NCT00908180	Jul 2009 → Jul 2014	lymphoma	Cancer Research UK	Unknown	Met primary
Phase 2	NCT00735436	Dec 2008 → Jul 2011	gliosarcoma	Duke University	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT00814593	Nov 2008 → Apr 2011	central nervous system neoplasm	Lisata Therapeutics, Inc.	Withdrawn	No outcome recorded
Phase 2	NCT00723658	Sep 2008 → May 2010	lymphoma	SWOG Cancer Research Network	Withdrawn	No outcome recorded Stop: Enrollment
Phase 2	NCT00632827	Jul 2008 → Jun 2014	peripheral T-cell lymphoma, not otherwise specified	University of California, San Francisco	Terminated	No outcome recorded
Phase 2	NCT00712582	Jul 2008 → Mar 2021	non-Hodgkin lymphoma	Memorial Sloan Kettering Cancer Center	Completed	No outcome recorded
Phase 2	NCT00716066	Jun 2008 → Dec 2025 overdue	Lambert-Eaton myasthenic syndrome, Rasmussen subacute encephalitis, central nervous system vasculitis, cerebellar degeneration +5	Fred Hutchinson Cancer Center	Active not recruiting	No outcome recorded
Phase 2	NCT00795665	Jun 2008 → Dec 2015	glioma	University of California, Davis	Completed	No outcome recorded
Phase 2	NCT00695409	Mar 2008 → Mar 2017	lymphoma	City of Hope Medical Center	Completed	No outcome recorded
Phase 2	NCT00669812	Feb 2008 → ?	lymphoma, small intestine cancer	Cancer Research UK	Unknown	No outcome recorded
Phase 2	NCT00525590	Dec 2007 → Dec 2010	metastatic malignant neoplasm in the brain	Eisai Inc.	Completed	No outcome recorded
Phase 2	NCT01148173	Oct 2007 → Oct 2011	non-Hodgkin lymphoma	Charite University, Berlin, Germany	Unknown	No outcome recorded
Phase 2	NCT00801216	Jan 2007 → Jan 2013	B-cell non-Hodgkin lymphoma	Andrés José Maria Ferreri	Completed	No outcome recorded
Phase 2	NCT00481832	Jan 2007 → Oct 2014	non-Hodgkin lymphoma	Stanford University	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT00349778	Aug 2006 → Apr 2009	plasma cell myeloma	Stanford University	Completed	No outcome recorded
Phase 2	NCT00288626	Jul 2006 → Nov 2015	relapsing-remitting multiple sclerosis	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT04755023	Dec 2005 → Mar 2009	oligodendroglial tumor	Assistance Publique Hopitaux De Marseille	Completed	No outcome recorded
Phase 2	NCT00233987	Oct 2005 → Nov 2014	lymphoma	SWOG Cancer Research Network	Completed	No outcome recorded
Phase 2	NCT00345865	Aug 2005 → Jun 2019	lymphoma	Masonic Cancer Center, University of Minnesota	Completed	No outcome recorded
Phase 2	NCT00472056	Mar 2005 → Jun 2012	lymphoma	M.D. Anderson Cancer Center	Completed	No outcome recorded
Phase 2	NCT00946374	Jul 2004 → Dec 2010	mantle cell lymphoma	Heidelberg University	Unknown	No outcome recorded
Phase 2	NCT00086879	May 2004 → Mar 2006	central nervous system neoplasm	European Organisation for Research and Treatment of Cancer - EORTC	Completed	Missed primary
Phase 2	NCT00362921	Apr 2004 → Aug 2007	brain neoplasm	Duke University	Completed	No outcome recorded
Phase 2	NCT00242996	Mar 2004 → Apr 2007	lymphoma	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Completed	No outcome recorded
Phase 2	NCT00080886	May 2002 → Nov 2005	lymphoma	University of Nebraska	Completed	No outcome recorded
Phase 2	NCT00003878	Apr 2002 → Apr 2003	cancer of unknown primary site, metastatic malignant neoplasm	New Approaches to Brain Tumor Therapy Consortium	Completed	No outcome recorded
Phase 2	NCT00791947	Oct 2001 → Aug 2008	peripheral T-cell lymphoma, not otherwise specified	University of Aarhus	Completed	No outcome recorded
Phase 2	NCT00020943	Jun 2001 → Dec 2006	lymphoma	Alliance for Clinical Trials in Oncology	Completed	No outcome recorded
Phase 2	NCT02099292	May 2001 → May 2005	non-Hodgkin lymphoma	Georg Hess, MD	Completed	No outcome recorded
Phase 2	NCT00006386	Mar 2001 → Nov 2004	central nervous system neoplasm	Radiation Therapy Oncology Group	Completed	Missed primary
Phase 2	NCT00006747	Nov 2000 → Feb 2003	graft versus host disease, lymphoma	Alliance for Clinical Trials in Oncology	Completed	No outcome recorded
Phase 2	NCT00007852	Sep 2000 → Jan 2002	lymphoma	University of Nebraska	Completed	No outcome recorded
Phase 2	NCT00005985	Aug 2000 → Feb 2007	lymphoma	Masonic Cancer Center, University of Minnesota	Completed	No outcome recorded
Phase 2	NCT00005081	Aug 2000 → Apr 2001	central nervous system neoplasm	Duke University	Completed	No outcome recorded
Phase 2	NCT00005066	Jun 2000 → Sep 2001	sarcoma	University of Chicago	Completed	No outcome recorded
Phase 2	NCT00005961	Jun 2000 → Dec 2005	cutaneous melanoma	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 2	NCT00005981	Jun 2000 → Nov 2003	colorectal cancer	Case Comprehensive Cancer Center	Completed	No outcome recorded
Phase 2	NCT00006656	Jun 2000 → ?	central nervous system neoplasm	Direct Therapeutics	Unknown	No outcome recorded
Phase 2	NCT00006695	Apr 2000 → Sep 2005	lymphoma	University of Nebraska	Completed	No outcome recorded
Phase 2	NCT00004072	Sep 1999 → Aug 2004	plasma cell myeloma	Case Comprehensive Cancer Center	Completed	No outcome recorded
Phase 2	NCT00003996	May 1999 → Aug 2001	central nervous system neoplasm	Alliance for Clinical Trials in Oncology	Completed	No outcome recorded
Phase 2	NCT00007982	Apr 1999 → Feb 2005	central nervous system neoplasm, head and neck cancer, lymphoma	Herbert Irving Comprehensive Cancer Center	Completed	No outcome recorded
Phase 2	NCT00003621	Feb 1999 → Feb 2005	central nervous system neoplasm	Alliance for Clinical Trials in Oncology	Completed	Missed primary
Phase 2	NCT00003401	Jan 1999 → Sep 2002	plasma cell myeloma	University of Maryland, Baltimore	Completed	No outcome recorded
Phase 2	NCT00003402	Jan 1999 → Dec 2002	leukemia, lymphoma	University of Maryland, Baltimore	Completed	No outcome recorded
Phase 2	NCT00003632	Sep 1998 → Jul 2005	lymphoma	Memorial Sloan Kettering Cancer Center	Completed	No outcome recorded
Phase 2	NCT00003399	Sep 1998 → Sep 2002	plasma cell myeloma	University of Maryland, Baltimore	Completed	No outcome recorded
Phase 2	NCT00003413	Sep 1998 → Feb 2001	ovarian cancer	University of Maryland, Baltimore	Completed	No outcome recorded
Phase 2	NCT00003400	Sep 1998 → Mar 2000	prostate cancer	University of Maryland, Baltimore	Completed	No outcome recorded
Phase 2	NCT00003397	Sep 1998 → Dec 2002	lymphoma	University of Maryland, Baltimore	Completed	No outcome recorded
Phase 2	NCT00014573	Aug 1998 → Oct 2004	brain cancer	Barbara Ann Karmanos Cancer Institute	Completed	No outcome recorded
Phase 2	NCT00003631	Aug 1998 → Apr 2010	lymphoma	Memorial Sloan Kettering Cancer Center	Completed	No outcome recorded
Phase 2	NCT00002941	Apr 1998 → Nov 2002	lymphoma	Children's Oncology Group	Completed	No outcome recorded
Phase 2	NCT00003176	Mar 1998 → Dec 2001	central nervous system neoplasm	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Completed	No outcome recorded
Phase 2	NCT00275015	Jan 1998 → Apr 2012	chronic lymphocytic leukemia/small lymphocytic lymphoma	German CLL Study Group	Completed	No outcome recorded
Phase 2	NCT00003467	Jan 1998 → Feb 2004	central nervous system neoplasm	Duke University	Completed	No outcome recorded
Phase 2	NCT00003346	Nov 1997 → Feb 2003	cutaneous melanoma	Memorial Sloan Kettering Cancer Center	Completed	No outcome recorded
Phase 2	NCT00002982	Jan 1997 → Oct 2005	lymphoma	Memorial Sloan Kettering Cancer Center	Completed	No outcome recorded
Phase 2	NCT00004688	Aug 1996 → Jul 1998	anaplastic astrocytoma, anaplastic oligodendroglioma, glioblastoma, mixed glioma +1	Emory University	Completed	No outcome recorded
Phase 2	NCT00002676	Jul 1995 → Oct 2006	lymphoma	Alliance for Clinical Trials in Oncology	Completed	No outcome recorded
Phase 2	NCT00002638	Mar 1995 → Mar 2005	leukemia	University of Nebraska	Completed	No outcome recorded
Phase 2	NCT00002552	Oct 1993 → Sep 2001	plasma cell neoplasm	Barbara Ann Karmanos Cancer Institute	Completed	No outcome recorded
Phase 2	NCT00060255	Dec 1991 → Aug 2006	breast cancer, childhood malignant neoplasm, leukemia, plasma cell neoplasm +1	Roswell Park Cancer Institute	Completed	No outcome recorded
Phase 2	NCT00610883	May 1990 → Dec 2008	non-Hodgkin lymphoma	Memorial Sloan Kettering Cancer Center	Completed	No outcome recorded
Phase 2	NCT00002461	Apr 1988 → Jul 1991	lymphoma	Montefiore Medical Center	Completed	No outcome recorded
Phase 2	NCT00046878	? → Aug 2002	central nervous system neoplasm	Duke University	Withdrawn	No outcome recorded

Phase 2/31 trial
Phase 2/3	NCT00096460	Aug 2004 → Mar 2006	follicular lymphoma	Medical College of Wisconsin	Terminated	No outcome recorded Stop: Enrollment
Phase 326 trials · 2 met primary · 5 missed
Phase 3	NCT03632135	May 2018 → Jun 2022	glioblastoma	Cordgenics, LLC	Completed	Met primary
Phase 3	NCT02858258	Jul 2016 → May 2021	mantle cell lymphoma	Prof. Dr. M. Dreyling (co-chairman)	Unknown	Mixed
Phase 3	NCT01656980	Aug 2012 → Aug 2014	anaplastic astrocytoma, anaplastic oligoastrocytoma, anaplastic oligodendroglioma, glioblastoma	Shandong Lanjin Pharmaceuticals Co.,Ltd	Unknown	No outcome recorded
Phase 3	NCT01827605	Jan 2012 → Oct 2019	follicular lymphoma	Fondazione Italiana Linfomi - ETS	Completed	Missed primary
Phase 3	NCT00920153	May 2008 → Mar 2016	lymphoma	French Innovative Leukemia Organisation	Terminated	No outcome recorded
Phase 3	NCT00499018	Jan 2006 → Jun 2011	diffuse large B-cell lymphoma	Fondazione Italiana Linfomi - ETS	Unknown	Met primary
Phase 3	NCT00076986	Feb 2004 → Mar 2007	glioblastoma	INSYS Therapeutics Inc	Completed	No outcome recorded
Phase 3	NCT00068952	Aug 2003 → Mar 2006	glioblastoma	Pfizer	Completed	No outcome recorded
Phase 3	NCT00017147	Sep 2001 → May 2006	brain cancer	SWOG Cancer Research Network	Completed	Missed primary
Phase 3	NCT00025636	Jul 2001 → ?	lymphoma	German Hodgkin's Lymphoma Study Group	Unknown	No outcome recorded
Phase 3	NCT00016887	Dec 2000 → ?	lymphoma	German Low Grade Lymphoma Study Group	Unknown	No outcome recorded
Phase 3	NCT00005090	Apr 2000 → May 2005	lymphoma	SWOG Cancer Research Network	Terminated	No outcome recorded Stop: Enrollment
Phase 3	NCT00560053	Jan 2000 → Feb 2005	plasma cell myeloma	PETHEMA Foundation	Completed	No outcome recorded
Phase 3	NCT00004031	Jul 1997 → Jun 2008	lymphoma	SWOG Cancer Research Network	Completed	Mixed
Phase 3	NCT00002772	Jul 1996 → Feb 2004	breast cancer	SWOG Cancer Research Network	Terminated	Missed primary Stop: Enrollment
Phase 3	NCT00002766	Mar 1996 → Sep 2011	leukemia, lymphoma	Memorial Sloan Kettering Cancer Center	Completed	No outcome recorded
Phase 3	NCT00002719	Dec 1995 → Nov 2001	leukemia, neutropenia	European Organisation for Research and Treatment of Cancer - EORTC	Completed	No outcome recorded
Phase 3	NCT00002835	Oct 1995 → Feb 2004	lymphoma	M.D. Anderson Cancer Center	Completed	No outcome recorded
Phase 3	NCT00002620	Nov 1994 → Jun 2000	brain cancer	European Organisation for Research and Treatment of Cancer - EORTC	Completed	Missed primary
Phase 3	NCT00002599	Sep 1994 → ?	plasma cell myeloma	Medical Research Council	Unknown	No outcome recorded
Phase 3	NCT00003815	Jun 1994 → ?	lymphoma	Scotland and Newcastle Lymphoma Group	Unknown	No outcome recorded
Phase 3	NCT00002545	Feb 1994 → Dec 2004	central nervous system neoplasm	Radiation Therapy Oncology Group	Completed	Missed primary
Phase 3	NCT00002548	Jan 1994 → Oct 2003	plasma cell myeloma	SWOG Cancer Research Network	Completed	No outcome recorded
Phase 3	NCT00002653	Sep 1993 → ?	plasma cell myeloma	Medical Research Council	Unknown	No outcome recorded
Phase 3	NCT00003578	Jan 1993 → ?	lymphoma	Lymphoma Trials Office	Unknown	No outcome recorded
Phase 3	NCT03722355	Nov 1990 → Mar 1994	astrocytoma (excluding glioblastoma), glioblastoma	Radiation Therapy Oncology Group	Completed	No outcome recorded

Phase not applicable5 trials
—	NCT01769911	Feb 2015 → Feb 2019	Burkitt lymphoma, Hodgkins lymphoma, MALT lymphoma, T-cell large granular lymphocyte leukemia +20	Fred Hutchinson Cancer Center	Withdrawn	No outcome recorded
—	NCT01637753	Jun 2012 → Jun 2013	anaplastic astrocytoma, anaplastic oligoastrocytoma, anaplastic oligodendroglioma, glioblastoma	Shandong Lanjin Pharmaceuticals Co.,Ltd	Unknown	No outcome recorded
—	NCT00536601	Jun 2006 → Jul 2018	Burkitt lymphoma, Ewing sarcoma/peripheral primitive neuroectodermal tumor, Hodgkins lymphoma, MALT lymphoma +24	Roswell Park Cancer Institute	Completed	No outcome recorded
—	NCT00317408	Apr 2004 → Feb 2014	lymphoma	European Inter-group Cooperation on Childhood and Adolescent Non Hodgkin Lymphoma	Unknown	No outcome recorded
—	NCT00544570	Apr 1998 → Dec 2007	lymphoma	City of Hope Medical Center	Completed	No outcome recorded
Comparator or background therapy103 trials
Phase 1	NCT05521984 Background	Apr 2023 → Mar 2031 expected	brain cancer, childhood malignant neoplasm	Washington University School of Medicine	Recruiting	No outcome recorded
Phase 1	NCT05228249 Background	Apr 2023 → Oct 2025	high grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement, primary mediastinal large B-cell lymphoma	Fred Hutchinson Cancer Center	Withdrawn	No outcome recorded Stop: Enrollment
Phase 1	NCT02342782 Background	Jun → Sep 2020	mature T-cell and NK-cell non-Hodgkin lymphoma, primary cutaneous T-cell non-Hodgkin lymphoma	City of Hope Medical Center	Completed	No outcome recorded
Phase 1	NCT03072771 Background	Aug 2017 → Apr 2021	diffuse large B-cell lymphoma	Washington University School of Medicine	Completed	No outcome recorded
Phase 1	NCT02483000 Background	Feb 2017 → Nov 2019	Burkitt lymphoma, diffuse large B-cell lymphoma, indolent B-cell non-Hodgkin lymphoma, mantle cell lymphoma	Fred Hutchinson Cancer Center	Terminated	No outcome recorded Stop: Business
Phase 1	NCT02504359 Background	Jul 2015 → Sep 2020	plasma cell leukemia, plasma cell myeloma	OHSU Knight Cancer Institute	Completed	No outcome recorded
Phase 1	NCT03113162 Background	May 2015 → May 2020	multiple sclerosis	Makati Medical Center	Unknown	No outcome recorded
Phase 1	NCT01840566 Background	Apr 2013 → Apr 2027 expected	non-Hodgkin lymphoma	Memorial Sloan Kettering Cancer Center	Active not recruiting	No outcome recorded
Phase 1	NCT01476839 Background	Nov 2012 → Jul 2021	Hodgkins lymphoma	City of Hope Medical Center	Completed	No outcome recorded
Phase 1	NCT00968760 Background	Jun 2011 → Apr 2020	B-cell non-Hodgkin lymphoma	M.D. Anderson Cancer Center	Completed	No outcome recorded
Phase 1	NCT00569985 Background	Jun 2007 → Nov 2019	lymphoma	City of Hope Medical Center	Completed	No outcome recorded
Phase 1	NCT00477035 Background	May 2006 → Mar 2011	leukemia, plasma cell myeloma	Sally Arai	Completed	No outcome recorded
Phase 1	NCT00244946 Background	Mar 2004 → Jan 2010	lymphoma	Barbara Ann Karmanos Cancer Institute	Completed	No outcome recorded
Phase 1	NCT00045721 Background	Mar 2003 → Jul 2004	central nervous system neoplasm	Pediatric Brain Tumor Consortium	Terminated	No outcome recorded Stop: Enrollment
Phase 1	NCT00004892 Background	Apr 2000 → ?	central nervous system neoplasm	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 1	NCT00058292 Background	Apr 2000 → Jun 2006	lymphoma	Northwestern University	Completed	No outcome recorded
Phase 1	NCT00005637 Background	Dec 1999 → Jun 2003	central nervous system cancer	Memorial Sloan Kettering Cancer Center	Completed	No outcome recorded
Phase 1	NCT00003463 Background	Jul 1998 → Jul 2002	central nervous system neoplasm	Duke University	Completed	No outcome recorded
Phase 1	NCT00003543 Background	Jun 1998 → Aug 2002	colorectal cancer	Memorial Sloan Kettering Cancer Center	Completed	No outcome recorded
Phase 1	NCT00003484 Background	Sep 1997 → Nov 2003	central nervous system neoplasm, neuroblastoma	Darell D. Bigner, MD, PhD	Completed	No outcome recorded
Phase 1	NCT00574509 Background	Mar 1996 → Nov 2014	lymphoma	University of Nebraska	Completed	No outcome recorded
Phase 1/2	NCT06626516 Comparator	Oct 2025 → Oct 2030 expected	uveal melanoma	Thomas Jefferson University	Recruiting	No outcome recorded
Phase 1/2	NCT05075681 Background	Nov 2021 → Jun 2024	disease related to hematopoietic stem cell transplant	Chinese PLA General Hospital	Unknown	No outcome recorded
Phase 1/2	NCT04582604 Background	Sep 2020 → Sep 2023	disease related to hematopoietic stem cell transplant	Chinese PLA General Hospital	Unknown	No outcome recorded
Phase 1/2	NCT03579927 Background	Oct 2019	diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma	M.D. Anderson Cancer Center	Withdrawn	No outcome recorded Stop: Business
Phase 1/2	NCT03583424 Background	Sep 2018 → Sep 2021	diffuse large B-cell lymphoma, disease related to hematopoietic stem cell transplant, marginal zone lymphoma	Ohio State University Comprehensive Cancer Center	Completed	No outcome recorded
Phase 1/2	NCT03382977 Comparator	Dec 2017 → Jul 2025	glioblastoma	VBI Vaccines Inc.	Terminated	No outcome recorded
Phase 1/2	NCT02797470 Background	Jun 2016 → May 2021 overdue	Burkitt lymphoma, HIV infectious disease, Hodgkins lymphoma, follicular lymphoma +3	AIDS Malignancy Consortium	Active not recruiting	No outcome recorded
Phase 1/2	NCT02059239 Background	Jun 2014 → Dec 2019	Hodgkins lymphoma, non-Hodgkin lymphoma	Weill Medical College of Cornell University	Completed	No outcome recorded
Phase 1/2	NCT01921387 Background	Oct 2013 → Jul 2017	Hodgkins lymphoma, T-cell non-Hodgkin lymphoma, mantle cell lymphoma	Fred Hutchinson Cancer Center	Completed	No outcome recorded
Phase 1/2	NCT01468311 Background	Oct 2011 → Nov 2014	Hodgkins lymphoma	National Cancer Institute (NCI)	Terminated	No outcome recorded Stop: Enrollment
Phase 1/2	NCT01035463 Background	Nov 2009 → Jul 2017	ALK-negative anaplastic large cell lymphoma, mantle cell lymphoma	University of Nebraska	Completed	No outcome recorded
Phase 1/2	NCT00571493 Background	Apr 2006 → Nov 2014	mantle cell lymphoma	University of Nebraska	Completed	No outcome recorded
Phase 1/2	NCT01538472 Background	Sep 2003 → Nov 2011	lymphoma	M.D. Anderson Cancer Center	Completed	No outcome recorded
Phase 1/2	NCT00006123 Background	Jul 2000	female breast carcinoma	Beth Israel Deaconess Medical Center	Withdrawn	No outcome recorded
Phase 1/2	NCT00005855 Background	Jul 2000 → Oct 2006	central nervous system neoplasm	New Approaches to Brain Tumor Therapy Consortium	Completed	No outcome recorded
Phase 1/2	NCT00005803 Background	Sep 1999 → Jan 2016	Hodgkins lymphoma, T-cell prolymphocytic leukemia, chronic lymphocytic leukemia/small lymphocytic lymphoma	Fred Hutchinson Cancer Center	Completed	No outcome recorded
Phase 1/2	NCT00572013 Background	May 1998 → Jan 2001	lymphoma	University of Nebraska	Completed	No outcome recorded
Phase 2	NCT07199296 Background	Jul 2025 → Jul 2028 expected	mantle cell lymphoma	Ruijin Hospital	Recruiting	No outcome recorded
Phase 2	NCT06692452 Background	Dec 2024 → Oct 2027	angioimmunoblastic T-cell lymphoma, enteropathy-associated T-cell lymphoma, monomorphic epitheliotropic intestinal T-cell lymphoma, peripheral T-cell lymphoma, not otherwise specified	Eric Jacobsen, MD	Withdrawn	No outcome recorded
Phase 2	NCT06377540 Background	Dec 2024 → Sep 2027 expected	classic Hodgkin lymphoma, disease related to hematopoietic stem cell transplant	Masonic Cancer Center, University of Minnesota	Recruiting	No outcome recorded
Phase 2	NCT06652165 Background	Nov 2024 → Nov 2026 expected	diffuse large B-cell lymphoma	Ruijin Hospital	Not yet recruiting	No outcome recorded
Phase 2	NCT06652139 Background	Nov 2024 → Nov 2026 expected	diffuse large B-cell lymphoma	Ruijin Hospital	Not yet recruiting	No outcome recorded
Phase 2	NCT05367856 Background	May 2022 → Jun 2024	T-cell non-Hodgkin lymphoma	Ruijin Hospital	Unknown	No outcome recorded
Phase 2	NCT05088226 Background	Dec 2021 → Jun 2030 expected	disease related to hematopoietic stem cell transplant	Chinese PLA General Hospital	Recruiting	No outcome recorded
Phase 2	NCT04871607 Background	Nov 2021 → Oct 2029 expected	Hodgkins lymphoma	City of Hope Medical Center	Recruiting	No outcome recorded
Phase 2	NCT03736616 Background	Aug 2019 → Sep 2023	diffuse large B-cell lymphoma	Swedish Medical Center	Unknown	No outcome recorded
Phase 2	NCT02896582 Background	Nov 2016 → Mar 2019	mantle cell lymphoma	The Lymphoma Academic Research Organisation	Completed	Met primary
Phase 2	NCT02570542 Background	Oct 2015 → Oct 2026 expected	diffuse large B-cell lymphoma	Memorial Sloan Kettering Cancer Center	Active not recruiting	No outcome recorded
Phase 2	NCT02278796 Comparator	Apr 2015 → Nov 2018	diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma	Insel Gruppe AG, University Hospital Bern	Completed	No outcome recorded
Phase 2	NCT02329080 Background	Dec 2014 → Aug 2019	diffuse large B-cell lymphoma	International Extranodal Lymphoma Study Group (IELSG)	Completed	No outcome recorded
Phase 2	NCT01969435 Background	Mar 2014 → Sep 2015	Hodgkins lymphoma, non-Hodgkin lymphoma	Washington University School of Medicine	Completed	No outcome recorded
Phase 2	NCT00992446 Background	Sep 2010 → Jun 2015	T-cell non-Hodgkin lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma	Fred Hutchinson Cancer Center	Completed	No outcome recorded
Phase 2	NCT01141712 Background	Apr 2010 → May 2015	HIV infectious disease, lymphoma	Medical College of Wisconsin	Completed	No outcome recorded
Phase 2	NCT00720447 Background	Nov 2008 → Nov 2010	lymphoma	Cancer Research UK	Unknown	No outcome recorded
Phase 2	NCT00863460 Background	Oct 2008 → May 2016	primary central nervous system lymphoma	Institut Curie	Unknown	Met primary
Phase 2	NCT00691015 Background	May 2008 → Apr 2014	leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease, myeloproliferative neoplasm +1	Barbara Ann Karmanos Cancer Institute	Completed	No outcome recorded
Phase 2	NCT00670631 Background	Feb 2008 → May 2012	plasma cell myeloma	Guido Tricot	Completed	No outcome recorded
Phase 2	NCT00646750 Background	Jan 2008 → Feb 2010	non-Hodgkin lymphoma	Spanish Lymphoma Cooperative Group	Completed	No outcome recorded
Phase 2	NCT00591630 Comparator	Nov 2007 → Mar 2020	diffuse large B-cell lymphoma	M.D. Anderson Cancer Center	Completed	No outcome recorded
Phase 2	NCT00521014 Background	Oct 2007 → Jul 2013	lymphoma	Memorial Sloan Kettering Cancer Center	Completed	No outcome recorded
Phase 2	NCT00536978 Background	Sep 2007 → Nov 2010	leukemia, lymphoma	M.D. Anderson Cancer Center	Completed	No outcome recorded
Phase 2	NCT00689169 Background	Aug 2007 → Jan 2011	diffuse large B-cell lymphoma	Lymphoma Study Association	Completed	No outcome recorded
Phase 2	NCT00439556 Background	Feb 2007 → Jun 2018	lymphoma	M.D. Anderson Cancer Center	Completed	No outcome recorded
Phase 2	NCT00482053 Background	Oct 2006 → May 2010	diffuse large B-cell lymphoma	Stanford University	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT01220297 Background	Aug 2006 → Aug 2010	Hodgkins lymphoma, acute graft versus host disease, leukemia, non-Hodgkin lymphoma	Stanford University	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT00350181 Background	Aug 2006 → Aug 2007	acute graft versus host disease, leukemia, non-Hodgkin lymphoma	Stanford University	Completed	No outcome recorded
Phase 2	NCT00281879 Comparator	Feb 2006 → Feb 2008	childhood malignant neoplasm, leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative neoplasm +1	OHSU Knight Cancer Institute	Terminated	No outcome recorded
Phase 2	NCT00505921 Background	Mar 2003 → Nov 2009	lymphoma	M.D. Anderson Cancer Center	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT00556127 Background	Jun 2002 → Sep 2006	diffuse large B-cell lymphoma	Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie	Completed	No outcome recorded
Phase 2	NCT00388349 Background	Sep 2001 → Mar 2008	Hodgkins lymphoma	Stanford University	Completed	No outcome recorded
Phase 2	NCT00276809 Background	Jun 2001 → Sep 2004	B-cell chronic lymphocytic leukemia	German CLL Study Group	Completed	No outcome recorded
Phase 2	NCT00005987 Background	Aug 2000 → Jul 2003	plasma cell myeloma	Masonic Cancer Center, University of Minnesota	Terminated	No outcome recorded
Phase 2	NCT00028665 Background	Jun 2000 → Mar 2005	lymphoma	Case Comprehensive Cancer Center	Completed	No outcome recorded
Phase 2	NCT00005998 Background	Jan 2000 → Mar 2003	lymphoma	Masonic Cancer Center, University of Minnesota	Withdrawn	No outcome recorded Stop: Enrollment
Phase 2	NCT00003727 Background	Mar 1999 → Mar 2005	leukemia	University of Maryland, Baltimore	Completed	No outcome recorded
Phase 2	NCT00559104 Comparator	Oct 1998 → Jul 2011	lymphoma	City of Hope Medical Center	Completed	No outcome recorded
Phase 2	NCT00005613 Background	Mar 1996 → Oct 2006	lymphoma	H. Lee Moffitt Cancer Center and Research Institute	Completed	No outcome recorded
Phase 2/3	NCT00070187 Background	Nov 2003 → Jun 2005	lymphoma	Children's Oncology Group	Completed	No outcome recorded
Phase 3	NCT05931263 Background	Jun 2023 → Feb 2026 overdue	peripheral T-cell lymphoma, not otherwise specified	The First Affiliated Hospital with Nanjing Medical University	Recruiting	No outcome recorded
Phase 3	NCT05466318 Comparator	Jul 2022 → Dec 2025	T-cell non-Hodgkin lymphoma, diffuse large B-cell lymphoma	Sichuan University	Unknown	No outcome recorded
Phase 3	NCT02443077 Background	Oct 2016 → Jun 2024 overdue	diffuse large B-cell lymphoma activated B-cell type	National Cancer Institute (NCI)	Active not recruiting	No outcome recorded
Phase 3	NCT02366663 Background	Jan 2015 → Oct 2016	diffuse large B-cell lymphoma	City of Hope Medical Center	Terminated	No outcome recorded
Phase 3	NCT02531841 Comparator	Jul 2014 → Nov 2017	diffuse large B-cell lymphoma	University Hospital Freiburg	Unknown	No outcome recorded
Phase 3	NCT00761280 Comparator	Dec 2008 → Feb 2012	anaplastic astrocytoma, glioblastoma	Isarna Therapeutics GmbH	Terminated	No outcome recorded Stop: Enrollment
Phase 3	NCT00574080 Background	Jul 2006 → Mar 2011	plasma cell myeloma	University of Arkansas	Terminated	No outcome recorded Stop: Enrollment
Phase 3	NCT00461747 Comparator	Mar 2006 → Dec 2008	plasma cell myeloma	PETHEMA Foundation	Completed	Met primary
Phase 3	NCT00329030 Comparator	Dec 2005 → Aug 2013	B-cell non-Hodgkin lymphoma, large-cell immunoblastic lymphoma	National Heart, Lung, and Blood Institute (NHLBI)	Completed	Missed primary
Phase 3	NCT00209222 Comparator	Jul 2004 → Dec 2014	mantle cell lymphoma	European Mantle Cell Lymphoma Network	Unknown	Met primary
Phase 3	NCT00137995 Background	Jun 2003 → Oct 2008	diffuse large B-cell lymphoma	Lymphoma Study Association	Completed	No outcome recorded
Phase 3	NCT00052923 Background	Mar 2003 → Jun 2006	lymphoma	Eastern Cooperative Oncology Group	Completed	No outcome recorded
Phase 3	NCT00012051 Background	Sep 2000 → Oct 2007	lymphoma	Commissie Voor Klinisch Toegepast Onderzoek	Completed	No outcome recorded
Phase 3	NCT00004259 Comparator	Jun 2000 → Feb 2015	central nervous system neoplasm	Radiation Therapy Oncology Group	Completed	Missed primary
Phase 3	NCT00005589 Background	Oct 1999 → Apr 2013	lymphoma	EBMT Solid Tumors Working Party	Completed	No outcome recorded
Phase 3	NCT00083551 Comparator	Aug 1998 → Aug 2014	plasma cell myeloma	University of Arkansas	Completed	No outcome recorded
Phase 3	NCT00003788 Background	Apr 1998 → ?	central nervous system cancer	Colorado Health Foundation	Unknown	No outcome recorded
Phase 3	NCT00002836 Background	Sep 1995 → Mar 2006	breast cancer	M.D. Anderson Cancer Center	Completed	No outcome recorded
Phase 3	NCT00002556 Background	Jul 1994 → Jan 2006	plasma cell myeloma	National Cancer Institute (NCI)	Completed	No outcome recorded
—	NCT05922384 Background	Jul 2023 → Sep 2025	HIV infectious disease, lymphoma	Affiliated Hospital of Guangdong Medical University	Unknown	No outcome recorded
—	NCT05863845 Background	Jun 2023 → Nov 2024	diffuse large B-cell lymphoma	Ruijin Hospital	Unknown	No outcome recorded
—	NCT05814718 Background	Apr 2023 → Dec 2025	disease related to hematopoietic stem cell transplant	First Affiliated Hospital Xi'an Jiaotong University	Unknown	No outcome recorded
—	NCT03591861 Background	May 2019 → Nov 2022	brain cancer	Washington University School of Medicine	Terminated	No outcome recorded Stop: Enrollment
—	NCT01702961 Background	Jun 2002 → Aug 2014	Hodgkins lymphoma	Baylor College of Medicine	Completed	No outcome recorded

News releases announcing trial results or a regulatory action · 4

Date	Issuer	Release
2024-04-03	VBI Vaccines Inc.	Results VBI Vaccines Presents Encouraging Early Tumor Response Data From Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma vbivaccines.com ↗ No tumor responses have been observed in the SoC arm
2024-01-01	Alembic Pharmaceuticals Ltd.	Regulatory Press Release USFDA Products Approvals For the Qtr ended 31st Dec, 2023 alembicpharmaceuticals.com ↗
2018-10-19	Impax Laboratories, LLC	Regulatory Amneal Announces Approval of Carmustine for Injection USP, 100 mg/vial - Preparing for Launch amneal.com ↗ Amneal Pharmaceuticals, Inc. (NYSE: AMRX), today announced that it has received FDA approval for a generic version of BiCNU ® (carmustine) for injection, 100 mg.
2015-09-02	Eisai Inc.	Regulatory EISAI CLEARS ALL-CASE SURVEILLANCE CONDITION FOR APPROVAL OF ANTICANCER DRUG GLIADEL® 7.7MG IMPLANT eisai.com ↗ The MHLW lifted this condition for approval after evaluating safety and efficacy data submitted by Eisai from patients with malignant glioma (558 cases for safety analysis, 536 cases for efficacy analysis).

All press releases naming this drug 11 releases

Date	Issuer	Release
2025-04-14	VIVUS LLC	VIVUS Announces Enrollment of 1st Patient Phase 2 Trial Assessing Ethanol Free Carmustine as Component of High Dose Chemotherapy Prior to Transplant in Patients with Hodgkin or Non Hodgkin Lym vivus.com ↗
2024-04-03	VBI Vaccines Inc.	VBI Vaccines Presents Encouraging Early Tumor Response Data From Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma vbivaccines.com ↗
2024-01-01	Alembic Pharmaceuticals Ltd.	Press Release USFDA Products Approvals For the Qtr ended 31st Dec, 2023 alembicpharmaceuticals.com ↗
2018-10-19	Impax Laboratories, LLC	Amneal Announces Approval of Carmustine for Injection USP, 100 mg/vial - Preparing for Launch amneal.com ↗
2015-09-02	Eisai Inc.	EISAI CLEARS ALL-CASE SURVEILLANCE CONDITION FOR APPROVAL OF ANTICANCER DRUG GLIADEL® 7.7MG IMPLANT eisai.com ↗
2015-04-24	Eisai Inc.	EISAI COMMENCES BUSINESS IN MEXICO, AIMS TO EXPAND CONTRIBUTION TO PATIENTS IN LATIN AMERICA ANTICANCER AGENTS HALAVEN® AND GLIADEL® NEWLY LAUNCHED eisai.com ↗
2013-11-25	Eisai Inc.	EISAI TO RECEIVE JAPAN MARKETING AUTHORIZATION HOLDER LICENSE FROM NOBELPHARMA FOR ANTINEOPLASTIC AGENT GLIADEL® 7.7 mg IMPLANT eisai.com ↗
2013-01-08	Eisai Inc.	NOBELPHARMA AND EISAI ANNOUNCE JAPAN LAUNCH OF ANTINEOPLASTIC AGENT GLIADEL® 7.7 mg IMPLANT eisai.com ↗
2012-12-18	Eisai Inc.	U.S. SUBSIDIARY EISAI INC. DIVESTS U.S. RIGHTS FOR ANTINEOPLASTIC GLIADEL® WAFER TO ARBOR PHARMACEUTICALS, INC. eisai.com ↗
2012-08-30	Bristol-Myers Squibb	Bristol-Myers Squibb Initiates Voluntary Recall of 10 Lots of BiCN(R) (carmustine for injection) Due to the Potential for Overfill bms.com ↗
2009-04-06	Eisai Inc.	License Agreement for GLIADEL® WAFER in Japan Signed eisai.com ↗

Evidence & citations 26 cited values

Every value below carries the sentence it was read from. 255 sources stand behind the page.

Field	Value	Cited text
Known as	carmustine	“Patients with chemotherapy-sensitive persistent or relapsed DLBCL were randomly assigned to receive iodine-131 tositumomab (dosimetric dose of 5 mCi on day -19 and therapeutic...” PMID 23478060 ↗ Mar 2013 209 “Four cycles of Induction therapy: Rituximab 375mg/m2 d1; Methotrexate 3.5g/m2 d2;Temozolomide 100mg/m2 d2-6; for patients who reach a CR, PR, or SD, will proceed to autologous...” NCT02399189 ↗ “The investigator prospectively evaluated the combination of Rituximab and Dexa-BEAM (dexamethasone, carmustine, etoposide, cytarabine, melphalan) followed by high dose therapy...” NCT02099292 ↗ “A Single-center, Randomized Controlled Clinical Study of Zanubrutinib Combined With Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preconditioning Regimen for...” NCT06652165 ↗ “The implantation of Carmustine Wafers (Gliadel) delivers carmustine- (3-bis 2-chloroethyl 1-1-nitrosourea (BCNU)) directly into the surgical cavity created after tumour resection.” NCT01310868 ↗ “PURPOSE: To determine the safety and toxicity of carmustine (BCNU) and temozolomide (TMZ) with radiotherapy (RT) in newly diagnosed anaplastic astrocytoma.” PMID 15234047 ↗ Jul 2004 “Carmustine (B) also known as BCNU Etoposide (E) Cytarabine (A) also known as Ara-C and cytosine arabinoside Melphalan (M) also known as alkeran” NCT00574509 ↗ “Busulfan, carmustine and cyclophosphamide will be given to you for 5 days.” NCT05425654 ↗ “Drug: carmustine Given IV Other Names: BCNU BiCNU bis-chloronitrosourea” NCT05922384 ↗ “day -6 Carmustine\* 300 mg/ m2 i.v. in 250ml dextrose 5% solution” NCT01827605 ↗ “Chemotherapy regimen with carmustine (BCNU) 300 mg/m2 on day -6” NCT02278796 ↗ Show 199 more sources
Known as	1,3-bis(2-chloroethyl)-1-nitrosourea	“To evaluate the toxic effects and maximum tolerated dose of topical carmustine [1,3-bis(2-chloroethyl)-1-nitrosourea] following intravenous O6-benzylguanine in the treatment of...” PMID 22250189 ↗ May 2012
Known as	BCNU	“Control chemotherapy treatment will be chosen from any of the following standard-of-care chemotherapy drugs or combinations: * Carboplatin; * Irinotecan; * Etoposide; *...” NCT03632135 ↗ 58 “PURPOSE: This New Approaches to Brain Tumor Therapy CNS Consortium study sought to determine the maximum-tolerated dose (MTD) of carmustine (BCNU) that can be implanted in...” PMID 12721262 ↗ May 2003 “VBMCP: Vincristine, 0,03 mg/Kg (iv) day 1, BCNU, 0,5 mg/Kg iv day 1, Cyclophosphamide, 10 mg/Kg iv day 1, Melfalán, 0,25 mg/Kg oral days 1 to 4 Prednisone, 1 mg/Kg oral days 1...” NCT00461747 ↗ “We investigated the effect of stereotactic radiosurgery (SRS) added to conventional external beam radiation therapy (EBRT) with carmustine (BCNU) on the survival of patients with GBM.” PMID 15465203 ↗ Nov 2004 “The implantation of Carmustine Wafers (Gliadel) delivers carmustine- (3-bis 2-chloroethyl 1-1-nitrosourea (BCNU)) directly into the surgical cavity created after tumour resection.” NCT01310868 ↗ “Patients with supratentorial GBM were treated with a combination of carmustine (BCNU) and conformal irradiation (dose levels: 66, 72, 78, 84 Gy, respectively).” PMID 19533025 ↗ Jun 2009 “Carmustine (B) also known as BCNU Etoposide (E) Cytarabine (A) also known as Ara-C and cytosine arabinoside Melphalan (M) also known as alkeran” NCT00574509 ↗ “Chemotherapy will begin on Day -6 with carmustine (BCNU), followed by etoposide (VP-16), cytosine arabinoside (ARA-C), and melphalan.” NCT00281879 ↗ “two different high-dose methotrexate-based protocols followed by high-dose carmustine/thiotepa (BCNU/TT) plus ASCT” PMID 22473593 ↗ Apr 2012 “A Phase II Trial of O6-Benzylguanine (NSC 637037) and BCNU (Carmustine) in Patients With Metatstatic Melanoma” NCT00005961 ↗ “BCNU (carmustine) 400 mg/m2 in 500 mL glucose 5% sol. in 1-hr infusion on day-6 of conditioning and ASCT” NCT02329080 ↗ Show 48 more sources
Known as	Becenun	ChEMBL registry synonym — accepted as the source's own label CHEMBL513 ↗
Known as	BiCNU	“BiCNU (Carmustine with Ethanol)” NCT06915246 ↗
Known as	Bis-Chloroethyl-Nitroso-Urea	“Bis-Chloroethyl-Nitroso-Urea (BCNU) withTemozolomide” NCT04755023 ↗
Known as	Camustine	ChEMBL registry synonym — accepted as the source's own label CHEMBL513 ↗
Known as	Carmubris	ChEMBL registry synonym — accepted as the source's own label CHEMBL513 ↗
Known as	Carmustina	ChEMBL registry synonym — accepted as the source's own label CHEMBL513 ↗
Known as	Carmustine medac (previously carmustine obvius)	ChEMBL registry synonym — accepted as the source's own label CHEMBL513 ↗
Known as	Carmustine obvius	ChEMBL registry synonym — accepted as the source's own label CHEMBL513 ↗
Known as	CASANT	“The product in this study, Carmustine Sustained Release Implant (CASANT), is similar to that of Gliadel wafer as for the API(Active Pharmaceutical Ingredient), but different as...” NCT01656980 ↗
Known as	DTI-015	“Patients receive neoadjuvant carmustine in ethanol (DTI-015) intratumorally under stereotactic guidance 45-90 minutes prior to craniotomy and tumor resection.” NCT00009854 ↗ 2 “Patients receive carmustine in ethanol (DTI-015) intratumorally over 5 minutes during stereotactic biopsy or open craniotomy.” NCT00006656 ↗ NCT00038441 ↗
Known as	FDA-0345	ChEMBL registry synonym — accepted as the source's own label CHEMBL513 ↗
Known as	Gliadel	“The implantation of Carmustine Wafers (Gliadel) delivers carmustine- (3-bis 2-chloroethyl 1-1-nitrosourea (BCNU)) directly into the surgical cavity created after tumour resection.” NCT01310868 ↗ 3 “At the time of surgery, patients receive up to 8 polifeprosan 20 wafers with carmustine (Gliadel) implanted into the resection cavity.” NCT00045721 ↗ NCT01186406 ↗ NCT00735436 ↗
Known as	Gliadel (carmustine wafers)	“Gliadel (carmustine wafers)” NCT01186406 ↗
Known as	Gliadel wafer (carmustine)	“Gliadel wafer (carmustine)” NCT00362921 ↗
Known as	Gliadel wafers	“Patients undergo surgical resection and receive up to 8 polifeprosan 20 with carmustine implants (Gliadel wafers) in the resected tumor cavity.” NCT00004892 ↗ 1 “polifeprosan 20 with carmustine implant (Gliadel wafers)” NCT00003878 ↗
Known as	NSC-409962	“Carmustine, BCNU, NSC-409962.” NCT00002620 ↗ 1 “BCNU Carmustine, NSC-409962” NCT00002599 ↗
Known as	SK-27702	ChEMBL registry synonym — accepted as the source's own label CHEMBL513 ↗
Known as	SRI-1720	ChEMBL registry synonym — accepted as the source's own label CHEMBL513 ↗
Known as	VI-0609	“VI-0609 (Carmustine with Propylene Glycol)” NCT06915246 ↗
Action	Inhibit	“Glutathione reductase inhibitor” CHEMBL513 ↗
Modality	Small molecule	“Carmustine is an alkylating agent.” NCT03072771 ↗
Route	Intravenous	“Patients without extensive prior radiotherapy undergo radiotherapy to areas of measurable active disease plus a 2 cm margin on days -21 to -17 and -14 to -8. Patients without a...” NCT00002461 ↗
Target	GSR	“Glutathione reductase inhibitor” CHEMBL513 ↗